Selected research
Industry Research
Radiopharmaceutical (Oral Route) Industry Research Report 2026
Market perspective
The global Radiopharmaceutical (Oral Route) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Radiopharmaceutical (Oral Route) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Radiopharmaceutical (Oral Route) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Radiopharmaceutical (Oral Route) include Eli Lilly, Bayer, Triad Isotopes, SIEMENS, Nordion, Navidea, Mallinckrodt, Lantheus and Jubilant Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Radiopharmaceutical (Oral Route) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Radiopharmaceutical (Oral Route) Market by Company
Eli Lilly
Bayer
Triad Isotopes
SIEMENS
Nordion
Navidea
Mallinckrodt
Lantheus
Jubilant Pharma
IBA Group
GE Healthcare
Dongcheng
China Isotope & Radiation
Bracco Imaging
Advanced Accelerator Applications
Radiopharmaceutical (Oral Route) Segment by Type
Actinium-225
Holmium-166
Radium-223
Lutetium-177
Other
Radiopharmaceutical (Oral Route) Segment by Application
Oncology
Cardiology
Other
Radiopharmaceutical (Oral Route) Segment by Region
North America
United States
Canada
Europe
v
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical (Oral Route) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical (Oral Route) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical (Oral Route).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Radiopharmaceutical (Oral Route) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Radiopharmaceutical (Oral Route) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Actinium-225
- Holmium-166
- Radium-223
- Lutetium-177
- Other
Applications
- Oncology
- Cardiology
- Other
Companies covered
- Eli Lilly
- Bayer
- Triad Isotopes
- SIEMENS
- Nordion
- Navidea
- Mallinckrodt
- Lantheus
- Jubilant Pharma
- IBA Group
- GE Healthcare
- Dongcheng
- China Isotope & Radiation
- Bracco Imaging
- Advanced Accelerator Applications
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Radiopharmaceutical (Oral Route) Market Size (2021-2032)
- 2.2.2 Global Radiopharmaceutical (Oral Route) Sales (2021-2032)
- 2.2.3 Global Radiopharmaceutical (Oral Route) Market Average Price (2021-2032)
- 2.3 Radiopharmaceutical (Oral Route) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Actinium-225
- 2.3.3 Holmium-166
- 2.3.4 Radium-223
- 2.3.5 Lutetium-177
- 2.3.6 Other
- 2.4 Radiopharmaceutical (Oral Route) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Oncology
- 2.4.3 Cardiology
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Radiopharmaceutical (Oral Route) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Radiopharmaceutical (Oral Route) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Radiopharmaceutical (Oral Route) Revenue of Manufacturers (2021-2026)
- 3.4 Global Radiopharmaceutical (Oral Route) Average Price by Manufacturers (2021-2026)
- 3.5 Global Radiopharmaceutical (Oral Route) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Radiopharmaceutical (Oral Route), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Radiopharmaceutical (Oral Route), Product Type & Application
- 3.8 Global Manufacturers of Radiopharmaceutical (Oral Route), Established Date
- 3.9 Global Radiopharmaceutical (Oral Route) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eli Lilly
- 4.1.1 Eli Lilly Company Information
- 4.1.2 Eli Lilly Business Overview
- 4.1.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio
- 4.1.5 Eli Lilly Recent Developments
- 4.2 Bayer
- 4.2.1 Bayer Company Information
- 4.2.2 Bayer Business Overview
- 4.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Radiopharmaceutical (Oral Route) Product Portfolio
- 4.2.5 Bayer Recent Developments
- 4.3 Triad Isotopes
- 4.3.1 Triad Isotopes Company Information
- 4.3.2 Triad Isotopes Business Overview
- 4.3.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio
- 4.3.5 Triad Isotopes Recent Developments
- 4.4 SIEMENS
- 4.4.1 SIEMENS Company Information
- 4.4.2 SIEMENS Business Overview
- 4.4.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio
- 4.4.5 SIEMENS Recent Developments
- 4.5 Nordion
- 4.5.1 Nordion Company Information
- 4.5.2 Nordion Business Overview
- 4.5.3 Nordion Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Nordion Radiopharmaceutical (Oral Route) Product Portfolio
- 4.5.5 Nordion Recent Developments
- 4.6 Navidea
- 4.6.1 Navidea Company Information
- 4.6.2 Navidea Business Overview
- 4.6.3 Navidea Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Navidea Radiopharmaceutical (Oral Route) Product Portfolio
- 4.6.5 Navidea Recent Developments
- 4.7 Mallinckrodt
- 4.7.1 Mallinckrodt Company Information
- 4.7.2 Mallinckrodt Business Overview
- 4.7.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio
- 4.7.5 Mallinckrodt Recent Developments
- 4.8 Lantheus
- 4.8.1 Lantheus Company Information
- 4.8.2 Lantheus Business Overview
- 4.8.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lantheus Radiopharmaceutical (Oral Route) Product Portfolio
- 4.8.5 Lantheus Recent Developments
- 4.9 Jubilant Pharma
- 4.9.1 Jubilant Pharma Company Information
- 4.9.2 Jubilant Pharma Business Overview
- 4.9.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio
- 4.9.5 Jubilant Pharma Recent Developments
- 4.10 IBA Group
- 4.10.1 IBA Group Company Information
- 4.10.2 IBA Group Business Overview
- 4.10.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 IBA Group Radiopharmaceutical (Oral Route) Product Portfolio
- 4.10.5 IBA Group Recent Developments
- 4.11 GE Healthcare
- 4.11.1 GE Healthcare Company Information
- 4.11.2 GE Healthcare Business Overview
- 4.11.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio
- 4.11.5 GE Healthcare Recent Developments
- 4.12 Dongcheng
- 4.12.1 Dongcheng Company Information
- 4.12.2 Dongcheng Business Overview
- 4.12.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio
- 4.12.5 Dongcheng Recent Developments
- 4.13 China Isotope & Radiation
- 4.13.1 China Isotope & Radiation Company Information
- 4.13.2 China Isotope & Radiation Business Overview
- 4.13.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio
- 4.13.5 China Isotope & Radiation Recent Developments
- 4.14 Bracco Imaging
- 4.14.1 Bracco Imaging Company Information
- 4.14.2 Bracco Imaging Business Overview
- 4.14.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio
- 4.14.5 Bracco Imaging Recent Developments
- 4.15 Advanced Accelerator Applications
- 4.15.1 Advanced Accelerator Applications Company Information
- 4.15.2 Advanced Accelerator Applications Business Overview
- 4.15.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio
- 4.15.5 Advanced Accelerator Applications Recent Developments
5 Global Radiopharmaceutical (Oral Route) Market Scenario by Region
- 5.1 Global Radiopharmaceutical (Oral Route) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Radiopharmaceutical (Oral Route) Sales by Region: 2021-2032
- 5.2.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2021-2026
- 5.2.2 Global Radiopharmaceutical (Oral Route) Sales by Region: 2027-2032
- 5.3 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2021-2032
- 5.3.1 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2021-2026
- 5.3.2 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2027-2032
- 5.4 North America Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
- 5.4.1 North America Radiopharmaceutical (Oral Route) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
- 5.4.3 North America Radiopharmaceutical (Oral Route) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
- 5.5.1 Europe Radiopharmaceutical (Oral Route) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
- 5.5.3 Europe Radiopharmaceutical (Oral Route) Revenue by Country (2021-2032)
- 5.5.4 v
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Radiopharmaceutical (Oral Route) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
- 5.7.1 South America Radiopharmaceutical (Oral Route) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
- 5.7.3 South America Radiopharmaceutical (Oral Route) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Radiopharmaceutical (Oral Route) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Radiopharmaceutical (Oral Route) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2021-2032)
- 6.1.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2021-2032)
- 6.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032)
- 6.2.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2021-2032)
- 6.3 Global Radiopharmaceutical (Oral Route) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2021-2032)
- 7.1.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2021-2032)
- 7.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032)
- 7.2.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2021-2032)
- 7.3 Global Radiopharmaceutical (Oral Route) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Radiopharmaceutical (Oral Route) Value Chain Analysis
- 8.1.1 Radiopharmaceutical (Oral Route) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Radiopharmaceutical (Oral Route) Production Mode & Process
- 8.2 Radiopharmaceutical (Oral Route) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Radiopharmaceutical (Oral Route) Distributors
- 8.2.3 Radiopharmaceutical (Oral Route) Customers
9 Global Radiopharmaceutical (Oral Route) Analyzing Market Dynamics
- 9.1 Radiopharmaceutical (Oral Route) Industry Trends
- 9.2 Radiopharmaceutical (Oral Route) Industry Drivers
- 9.3 Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges
- 9.4 Radiopharmaceutical (Oral Route) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst